Table of Contents Author Guidelines Submit a Manuscript
International Journal of Endocrinology
Volume 2014, Article ID 581594, 8 pages
http://dx.doi.org/10.1155/2014/581594
Research Article

Reevaluation of Acromegalic Patients in Long-Term Remission according to Newly Proposed Consensus Criteria for Control of Disease

1Endocrinology and Diabetology Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Padiglione Granelli, Via F. Sforza 35, 20122 Milan, Italy
2Department of Clinical Sciences and Community Health, University of Milan, 20122 Milan, Italy
3Unit of Endocrine Diseases and Diabetology, Ospedale San Giuseppe Multimedica, 20123 Milan, Italy
4Endocrine Unit, IRCCS Humanitas Clinical Institute, 20089 Rozzano, Italy
5Department of Medicine Biotechnology and Translational Medicine, University of Milan, 20122 Milan, Italy
6Endocrine and Diabetes Unit, Department of Internal Medicine I, University Hospital of Würzburg, 97070 Würzburg, Germany

Received 26 August 2014; Accepted 24 November 2014; Published 21 December 2014

Academic Editor: Amelie Bonnefond

Copyright © 2014 Elisa Verrua et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Sherlock, J. Ayuk, J. W. Tomlinson et al., “Mortality in patients with pituitary disease,” Endocrine Reviews, vol. 31, no. 3, pp. 301–342, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. I. M. Holdaway, M. J. Bolland, and G. D. Gamble, “A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly,” European Journal of Endocrinology, vol. 159, no. 2, pp. 89–95, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. M. E. Sughrue, E. F. Chang, R. A. Gabriel, M. K. Aghi, and L. S. Blevins, “Excess mortality for patients with residual disease following resection of pituitary adenomas,” Pituitary, vol. 14, no. 3, pp. 276–283, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. M. Arosio, G. Reimondo, E. Malchiodi et al., “Predictors of morbidity and mortality in acromegaly: an Italian survey,” European Journal of Endocrinology, vol. 167, no. 2, pp. 189–198, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. A. Colao, R. Pivonello, L. M. Cavallo et al., “Age changes the diagnostic accuracy of mean profile and nadir growth hormone levels after oral glucose in postoperative patients with acromegaly,” Clinical Endocrinology, vol. 65, no. 2, pp. 250–256, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. A. M. Arafat, M. Möhlig, M. O. Weickert et al., “Growth hormone response during oral glucose tolerance test: the impact of assay method on the estimation of reference values in patients with acromegaly and in healthy controls, and the role of gender, age, and body mass index,” The Journal of Clinical Endocrinology and Metabolism, vol. 93, no. 4, pp. 1254–1262, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. L. Cazabat, J.-C. Souberbielle, and P. Chanson, “Dynamic tests for the diagnosis and assessment of treatment efficacy in acromegaly,” Pituitary, vol. 11, no. 2, pp. 129–139, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. A. Giustina, A. Barkan, F. F. Casanueva et al., “Criteria for cure of acromegaly: a consensus statement,” Journal of Clinical Endocrinology and Metabolism, vol. 85, no. 2, pp. 526–529, 2000. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Giustina, P. Chanson, M. D. Bronstein et al., “A consensus on criteria for cure of acromegaly,” The Journal of Clinical Endocrinology & Metabolism, vol. 95, no. 7, pp. 3141–3148, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. P. J. Trainer, J. Barth, C. Sturgeon, and G. Wieringa, “Consensus statement on the standardisation of GH assays,” European Journal of Endocrinology, vol. 155, no. 1, pp. 1–2, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. C. L. Ronchi, M. Arosio, E. Rizzo, A. G. Lania, P. Beck-Peccoz, and A. Spada, “Adequacy of current postglucose GH nadir limit (< 1 μg/l) to define long-lasting remission of acromegalic disease,” Clinical Endocrinology, vol. 66, no. 4, pp. 538–542, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. G. Corneli, C. Di Somma, R. Baldelli et al., “The cut-off limits of the GH response to GH-releasing hormone-arginine test related to body mass index,” European Journal of Endocrinology, vol. 153, no. 2, pp. 257–264, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. R. D. Murray, S. R. Peacey, A. Rahim, A. A. Toogood, M. O. Thorner, and S. M. Shalet, “The diagnosis of growth hormone deficiency (GHD) in successfully treated acromegalic patients,” Clinical Endocrinology, vol. 54, no. 1, pp. 37–44, 2001. View at Publisher · View at Google Scholar · View at Scopus
  14. C. Giavoli, E. Profka, E. Verrua et al., “GH replacement improves quality of life and metabolic parameters in cured acromegalic patients with growth hormone deficiency,” The Journal of Clinical Endocrinology and Metabolism, vol. 97, no. 11, pp. 3983–3988, 2012. View at Publisher · View at Google Scholar · View at Scopus
  15. A. L. Barkan, I. Halasz, K. J. Dornfeld et al., “Pituitary irradiation is ineffective in normalizing plasma insulin-like growth factor I in patients with acromegaly,” Journal of Clinical Endocrinology and Metabolism, vol. 82, no. 10, pp. 3187–3191, 1997. View at Publisher · View at Google Scholar · View at Scopus
  16. A. A. Van Der Klaauw, A. M. Pereira, S. W. van Thiel et al., “Attenuated pulse size, disorderly growth hormone and prolactin secretion with preserved nyctohemeral rhythm distinguish irradiated from surgically treated acromegaly patients,” Clinical Endocrinology, vol. 66, no. 4, pp. 489–498, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Bidlingmaier and P. U. Freda, “Measurement of human growth hormone by immunoassays: current status, unsolved problems and clinical consequences,” Growth Hormone and IGF Research, vol. 20, no. 1, pp. 19–25, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. A. Müller, M. Scholz, O. Blankenstein et al., “Harmonization of growth hormone measurements with different immunoassays by data adjustment,” Clinical Chemistry and Laboratory Medicine, vol. 49, no. 7, pp. 1135–1142, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. P. U. Freda, “Monitoring of acromegaly: what should be performed when GH and IGF-1 levels are discrepant?” Clinical Endocrinology, vol. 71, no. 2, pp. 166–170, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. L. Boero, M. Manavela, K. Danilowicz et al., “Comparison of two immunoassays in the determination of IGF-I levels and its correlation with oral glucose tolerance test (OGTT) and with clinical symptoms in acromegalic patients,” Pituitary, vol. 15, no. 4, pp. 466–471, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. P. U. Freda, “Current concepts in the biochemical assessment of the patient with acromegaly,” Growth Hormone and IGF Research, vol. 13, no. 4, pp. 171–184, 2003. View at Publisher · View at Google Scholar · View at Scopus
  22. E. Verrua, M. Filopanti, C. L. Ronchi et al., “GH response to oral glucose tolerance test: a comparison between patients with acromegaly and other pituitary disorders,” The Journal of Clinical Endocrinology & Metabolism, vol. 96, no. 1, pp. E83–E88, 2011. View at Publisher · View at Google Scholar · View at Scopus